网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
宫颈腺癌组织VIM、PR、Inhibin α蛋白表达及意义
作者:杨雪琴 
单位:四川省西昌市凉山彝族自治州中西医结合医院 妇产科, 四川 西昌 615000
关键词:宫颈腺癌 波形蛋白 孕激素受体 抑制素α 手术 残端复发 
分类号:R737.33;R446.8
出版年·卷·期(页码):2022·50·第八期(980-987)
摘要:

目的:检测宫颈腺癌组织波形蛋白(VIM)、孕激素受体(PR)、抑制素α(Inhibin α)蛋白表达,并分析其意义。方法:选取104例宫颈腺癌根治术后患者,免疫组化法检测癌组织和癌旁组织上述蛋白表达。患者均通过复查方式进行为期1年的随访,观察残端复发情况,并分析上述蛋白阳性表达与根治术后残端复发的关系。结果:宫颈腺癌组织VIM蛋白阳性表达率较高(P<0.05),PR、Inhibin α蛋白阳性表达率均较低(P<0.05);临床分期≥Ⅱb期、未/低分化、有脉管瘤栓、有盆腔淋巴结转移患者宫颈腺癌组织VIM蛋白阳性表达率均较高(P<0.05),PR、Inhibin α蛋白阳性表达率均较低(P<0.05),上述特征及宫颈腺癌组织VIM、PR、Inhibin α蛋白阳性表达均可影响患者根治术后残端复发(P<0.05)。结论:宫颈腺癌组织VIM蛋白阳性表达率高,PR、Inhibin α蛋白阳性表达率低,三者与临床病理特征、根治术后残端复发有关。

Objective: To detect the protein expressions of vimentin (VIM),progesterone receptor (PR) and inhibition α(Inhibin α) in cervical adenocarcinoma,and to analyze their significance.Methods: 104 patients with cervical adenocarcinoma were selected,and the protein expressions were detected by immunohistochemical method.All patients were followed up for one year by reexamination,the recurrence of stump was observed,and the relationships between the positive expressions of the above proteins and the recurrence of stump after radical operation were analyzed.Results: The positive expression rate of VIM protein in cervical adenocarcinoma was higher (P<0.05),while the positive expression rates of PR,Inhibin α were lower (P<0.05).The positive expression rates of VIM protein in cervical adenocarcinoma in patients with clinical stage ≥ Ⅱb,undifferentiated/poorly differentiated,vascular tumor thrombus and pelvic lymph node metastasis were higher (P<0.05),while PR and Inhibin α were lower (P<0.05).The characteristics,VIM,PR and Inhibin α protein positive expressions in cervical adenocarcinoma affected the risk factors for residual recurrence after radical resection (P<0.05).Conclusion: The positive expression rate of VIM protein in cervical adenocarcinoma is high,while PR and Inhibin α are low,which are related to the clinical characteristics and residual recurrence after radical operation.

参考文献:

[1] 曹毛毛,陈万青.中国恶性肿瘤流行情况及防控现状[J].中国肿瘤临床,2019,46(3):47-51.
[2] 吕炳建,石海燕,邵颖,等.基于国际颈管腺癌标准与分类286例宫颈腺癌临床病理与预后分析[J].中华病理学杂志,2021,50(9):1014-1019.
[3] JONSKA-GMYREK J,GMYREK L,ZOLCIAK-SIWINSKA A,et al.Adenocarcinoma histology is a poor prognostic factor in locally advanced cervical cancer[J].Curr Med Res Opin,2019,35(4):595-601.
[4] ALVARADO-CABRERO I,MCCLUGGAGE W G,ESTEVEZ-CASTRO R,et al.Micropapillary cervical adenocarcinoma:a clinicopathologic study of 44 cases[J].Am J Surg Pathol,2019,43(6):802-809.
[5] 蒋艳平,张赛,王前,等.钙联蛋白A9和波形蛋白在子宫颈癌及其淋巴结中的表达及意义[J].实用妇产科杂志,2020,36(12):920-925.
[6] NEYAZ A,HUSAIN N,DEODHAR M,et al.Synchronous cervical minimal deviation adenocarcinoma,gastric type adenocarcinoma and lobular endocervical glandular hyperplasia along with stil in peutz-jeghers syndrome:eliciting oncogenesis pathways[J].Turk Patoloji Derg,2019,35(3):247-253.
[7] 郭云鸿,王瑞芳,田晓予.卵巢子宫内膜样腺癌组织中细胞角蛋白、CA125、抑制素α的表达及临床意义[J].临床与病理杂志,2020,40(3):601-609.
[8] 张帆.妇科恶性肿瘤治疗学概要及述评[M].武汉:湖北科学技术出版社,2015.
[9] 于忠梁,王金兰,吕文,等.不同病理类型宫颈癌患者根治术后复发情况及危险因素分析[J].系统医学,2017,2(5):4-6,13.
[10] MASLOV D,BRAGG J.Left cervical lymphadenopathy presentation of metastatic colorectal adenocarcinoma[J].Ochsner J,2019,19(4):410-412.
[11] 李冰,马起鹏,林林,等.Prospero相关同源异形盒蛋白1在宫颈癌组织中的表达及其临床意义[J].东南大学学报(医学版),2021,40(3):376-380.
[12] 霍叶琳,王月,房国涛.宫颈癌脱落细胞RBL1启动子甲基化与患者放疗抵抗的关系[J].东南大学学报(医学版),2022,41(2):198-203.
[13] TEIXEIRA L N,JANNER E C,TEIXEIRA T,et al.Comparison of p63/p40 expression with myoepithelial markers in minor salivary gland tumors[J].Int J Surg Pathol,2019,27(4):360-371.
[14] LI X,HUANG Y,GUO S,et al.Exogenous regucalcin negatively regulates the progression of cervical adenocarcinoma[J].Oncol Lett,2019,18(1):609-616.
[15] 胡庆伟,邓再兴,王军,等.抑制素α、βA、βB在正常子宫内膜中的表达[J].实用妇产科杂志,2009,25(1):25-27.
[16] 贾海清,王安娜,龙再秋.早期子宫颈腺癌预后影响因素分析[J].中国实用妇科与产科杂志,2019,35(12):1374-1378.
[17] DE JUAN A,REDONDO A,RUBIO M J,et al.SEOM clinical guidelines for cervical cancer (2019)[J].Clin Transl Oncol,2020,22(2):270-278.
[18] CHEN J H,DUAN H,YU X B,et al.Clinical features and prognostic factors of cervical villoglandular adenocarcinoma[J].Int J Gynecol Cancer,2021,31(4):512-517.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 752393 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541